D-0891-2018 Class II Terminated

Recalled by Ingenus Pharmaceuticals Llc — Orlando, FL

FDA drug recall D-0891-2018 was initiated by Ingenus Pharmaceuticals Llc on Jun 8, 2018 and is designated Class II. Reason for recall: Superpotent Drug: High out of specification assay value results for potency. The recall status is terminated (terminated May 1, 2019). Affected quantity: 14089 vials.

Recall details

Product Type
Drugs
Report Date
Jul 11, 2018
Initiation Date
Jun 8, 2018
Termination Date
May 1, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
14089 vials

Product description

Irinotecan Hydrochloride Injection, USP, 40 mg/2 mL (20 mg/mL), 1 x 2 mL Single Dose Vial, Rx Only, Manufactured for: Ingenius Pharmaceuticals, LLC, Orlando, FL 32839-6408; Manufactured by: Ingenius Pharmaceuticals, GmbH Ticino 6917, Switzerland, NDC 50742-401-02.

Reason for recall

Superpotent Drug: High out of specification assay value results for potency.

Distribution pattern

Nationwide in the USA

Code information

Lot #: 17034-2, 17035-2, 17036-2; Exp. 08/19

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0891-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0891-2018. Report a data issue: hello@regdatalab.com.